期刊文献+

In vitro - in vivo - in silico approach in the development of inhaled drug products: Nanocrystal-based formulations with budesonide as a model drug

下载PDF
导出
摘要 This study aims to understand the absorption patterns of three different kinds of inhaled formulations via in silico modeling using budesonide(BUD)as a model drug.The formulations investigated in this study are:(i)commercially available micronized BUD mixed with lactose(BUD-PT),(ii)BUD nanocrystal suspension(BUD-NC),(iii)BUD nanocrystals embedded hyaluronic acid microparticles(BUD-NEM).The deposition patterns of the three inhaled formulations in the rats’lungs were determined in vivo and in silico predicted,which were used as inputs in GastroPlus TM software to predict drug absorption following aerosolization of the tested formulations.BUD pharmacokinetics,estimated based on intravenous data in rats,was used to establish a drug-specific in silico absorption model.The BUD-specific in silico model revealed that drug pulmonary solubility and absorption rate constant were the key factors affecting pulmonary absorption of BUD-NC and BUD-NEM,respectively.In the case of BUD-PT,the in silico model revealed significant gastrointestinal absorption of BUD,which could be overlooked by traditional in vivo experimental observation.This study demonstrated that in vitro-in vivo-in silico approach was able to identify the key factors that influence the absorption of different inhaled formulations,which may facilitate the development of orally inhaled formulations with different drug release/absorption rates.
出处 《Asian Journal of Pharmaceutical Sciences》 SCIE CAS 2021年第3期350-362,共13页 亚洲药物制剂科学(英文)
基金 This work was supported by National Natural Science Foundation of China(Nos.81302720 and No.81573380) Liaoning Pan Deng Xue Zhe Scholarship supported by the Ministry of Education,Science and Technological Development,Republic of Serbia(grant number 451-03-68/2020-14/200161) Cun D.is grateful to Liaoning Provincial Education officer’s Excellent Talents Supporting Plan for financial support.
  • 相关文献

参考文献2

二级参考文献87

  • 1Lipinski C. Poor aqueous solubility-an industry wide problem in drug discovery. American Pharmaceutical Review, 2002, 5:82-85.
  • 2Peters K, Muller R H. Nanosuspensions for the formulation of poorly soluble drugs I. Preparation by a size reduction technique. International Journal of Pharmaceutics, 1998, 160(2): 229-237.
  • 3Fromming K H S, Fromming J. Cyclodextrines in Pharmacy. Dordrecht: Kluwer Academic, 1993.
  • 4Muller R H. Dispersions for the formulation of slightly or poorly soluble drugs. US Patent, 7060285, 2001.
  • 5Muller B W, Rasenack N. Micro-size drug particles: Common and novel micronization techniques. Pharmaceutical Development and Technology, 2003, 9:1-13.
  • 6Zhang D, Chen M, Gao L. Drag nanocrystals for the formulation of poorly solubledrugs and its application as a potential drug delivery system. Journal of Nanoparticle Research, 2008, 10(5): 845-862.
  • 7Park J Y, Zhang Y, Liu F. Targeted cancer therapy with novel high drug-loading nanocrystals. Journal of Pharmaceutical Sciences, 2010, 99(8): 3542-3551.
  • 8Luna I P, Sntmdhar K B, Khatun S. Increasing possibilities of nanosuspension. Journal of Nanotechnology, 2013, 346581:1-12.
  • 9Abhijit A D, Kulkami R M, Patravale V B. Nanosuspensions: A promising drug delivery strategy. Joumal of Pharmacy and Pharmacology, 2004, 56(7): 827-840.
  • 10Moschwitzer J P, Muller R H, Sinha B. Bottom-up approaches for preparing drug nanocrystals: Formulations and factors affecting particle size. Intemational Journal of Pharmaceutics, 2013, 453(1): 126-141.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部